KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Current Leases (2019 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Current Leases for 7 consecutive years, with $36.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases fell 13.43% to $36.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.1 million, a 13.43% decrease, with the full-year FY2025 number at $36.1 million, down 13.43% from a year prior.
  • Current Leases was $36.1 million for Q4 2025 at Bio-Rad Laboratories, down from $36.8 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $42.8 million in Q3 2024 to a low of $34.0 million in Q3 2022.
  • A 5-year average of $38.2 million and a median of $36.8 million in 2025 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: increased 14.9% in 2023, then decreased 14.09% in 2025.
  • Bio-Rad Laboratories' Current Leases stood at $36.4 million in 2021, then dropped by 0.27% to $36.3 million in 2022, then grew by 11.18% to $40.4 million in 2023, then grew by 3.22% to $41.7 million in 2024, then fell by 13.43% to $36.1 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Current Leases are $36.1 million (Q4 2025), $36.8 million (Q3 2025), and $39.3 million (Q2 2025).